ClinicalTrials.gg
CompletedNCT00871351Updated May 23, 2024Results posted

Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)

A Phase 4 interventional study of Ezetimibe and Atorvastatin in Primary Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-23.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
58th of 97
125 · median 148
Started
2009
with 5 others
Phase 4
31 of 98
1 open now
Registered
59th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 58th largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2009, is one of 31 in phase 4, and was the 59th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of atorvastatin 10 mg and ezetimibe 10 mg coadministration in Japanese participants with hypercholesterolemia whose low-density lipoprotein (LDL)-cholesterol levels have not reached the lipid management target value with atorvastatin 10 mg alone, versus increasing the dose of atorvastatin to 20 mg or changing to rosuvastatin 2.5 mg.

03

Conditions studied

  • Primary Hypercholesterolemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • atorvastatin 10 mg monotherapy for 4 weeks or longer before the start of the 4-week washout and low density lipoprotein-cholesterol (LDL-C) levels that had not reached the following lipid management target values during treatment: Category I (low-risk group) with no other risk factors - LDL-C \<160 mg/dL; Category II (mid-risk group) with 1-2 risk factors other than LDL-C levels - LDL-C \<140 mg/dL; Category III (high-risk group) with 3 or more other risk factors - LDL-C \<120 mg/dL; and for participants with history of coronary artery disease - LDL-C \<100 mg/dL.
  • outpatient men or women, age 20 years and older

Exclusion criteria

Exclusion Criteria:

  • fasted triglyceride level at the start of washout or treatment period exceeding 400 mg/dL.
  • homozygous familial hypercholesterolemia.
  • creatine phosphokinase (CPK) >2 times the (X ULN) at start of washout or treatment period.
  • glycosylated () >=8% at start of washout or treatment period.
  • severe hepatic function disorder, or (AST) or alanine aminotransferase (ALT) >2X ULN at start of washout or treatment period.
  • to ezetimibe, atorvastatin, or rosuvastatin tablets.
  • pregnant or lactating
  • discontinued use of atorvastatin 10 mg for less than 4 weeks at start of treatment period (however, if participant had taken atorvastatin 10 mg before the test conducted at the start of the observation period, a period of discontinuation of 27 days is allowed.)
  • cyclosporine treatment
  • hyperlipidemia associated with hypothyroidism, obstructive gall bladder or biliary disease, chronic renal failure, and/or pancreatitis.
  • hyperlipidemia associated with drug administration that causes adverse serum lipid effects.
  • participation in a clinical study within 4 weeks of washout
  • cancer or cancer history within previous 5 years, except for successfully treated basal cell carcinoma of the skin.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Ezetimibe + Atorvastatin

    Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg

    Drug: Ezetimibe · Drug: Atorvastatin

  • Active comparator
    Atorvastatin

    Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg

    Drug: Atorvastatin

  • Active comparator
    Rosuvastatin

    Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg

    Drug: Rosuvastatin

Interventions

  • 1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)

    Also known as: SCH 058235

  • 1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)

  • 2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)

  • 1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)

06

What researchers measure

Primary outcomes

  1. Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values

    LDL-C was measured before group study drug administration (Week 4, end of atorvastatin single therapy) and at the end of study drug administration (after 12 weeks of study drug treatment, or at discontinuation).

    Time frame: End of Week 4 to Week 16 or discontinuation

Secondary outcomes

  1. Percent Change in LDL-C

    LDL-C was measured at the start of the atorvastatin 10 mg treatment period (end of the washout period) and at the end of administration of the study drug (Week 16 or discontinuation).

    Time frame: End of washout period to Week 16 or discontinuation

  2. Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values

    LDL-C was measured at the end of administration of the study drug (Week 16 or discontinuation). Target values: For participants with history of coronary artery disease: \<100 mg/dL; for participants with at least 3 cardiovascular (CV) risk factors: \<120 mg/dL; for participants with 1-2 CV risk factors: \<140 mg/dL; for participants with no CV risk factors: \<160 mg/dL.

    Time frame: Week 16 or discontinuation

  3. Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)

    Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at 4 weeks after the start of the treatment period (after completion of administration of atorvastatin 10 mg alone) and at Week 16 or at discontinuation.

    Time frame: End of Week 4 to Week 16 or discontinuation

  4. Percent Change in Total Lipids and Hs-CRP

    Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at the start of the treatment period (at start of administration of atorvastatin 10 mg alone) and at the end of study drug (Week 16 or discontinuation).

    Time frame: End of washout to Week 16 or discontinuation

07

Results

Posted Aug 23, 2011

Participant flow

Participant flow — Overall Study
MilestoneEzetimibe + AtorvastatinAtorvastatinRosuvastatin
Started474632
Completed434532
Not completed410
Withdrew: Withdrawal by subject100
Withdrew: Adverse event310

Outcome measures

PrimaryPercent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values

LDL-C was measured before group study drug administration (Week 4, end of atorvastatin single therapy) and at the end of study drug administration (after 12 weeks of study drug treatment, or at discontinuation).

Time frame:
End of Week 4 to Week 16 or discontinuation
Reported as:
Mean · Percent change
Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values
Percent changeEzetimibe + AtorvastatinAtorvastatinRosuvastatin
Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values-25.8 (-29.2 to -22.4)-15.1 (-18.6 to -11.7)0.8 (-3.3 to 4.9)
Statistical analysis
  • Ezetimibe + Atorvastatin vs Atorvastatin · Hochberg's method · p = <0.0001 · Mean difference (net): -10.6 · 95% CI -15.4 to -5.8
  • Ezetimibe + Atorvastatin vs Rosuvastatin · Hochberg's method · p = <0.0001 · Mean difference (net): -26.5 · 95% CI -31.8 to -21.2
SecondaryPercent Change in LDL-C

LDL-C was measured at the start of the atorvastatin 10 mg treatment period (end of the washout period) and at the end of administration of the study drug (Week 16 or discontinuation).

Time frame:
End of washout period to Week 16 or discontinuation
Reported as:
Mean · Percent change
Percent Change in LDL-C
Percent changeEzetimibe + AtorvastatinAtorvastatinRosuvastatin
Percent Change in LDL-C-49.6 (-52.9 to -46.4)-41.1 (-44.4 to -37.9)-30.5 (-34.4 to -26.6)
Statistical analysis
  • Ezetimibe + Atorvastatin vs Atorvastatin · Hochberg's method · p = 0.0003
  • Ezetimibe + Atorvastatin vs Rosuvastatin · Hochberg's method · p = <0.0001
SecondaryNumber of Participants Whose LDL-C Levels Reached the Lipid Management Target Values

LDL-C was measured at the end of administration of the study drug (Week 16 or discontinuation). Target values: For participants with history of coronary artery disease: \<100 mg/dL; for participants with at least 3 cardiovascular (CV) risk factors: \<120 mg/dL; for participants with 1-2 CV risk factors: \<140 mg/dL; for participants with no CV risk factors: \<160 mg/dL.

Time frame:
Week 16 or discontinuation
Reported as:
Number · Participants
Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values
ParticipantsEzetimibe + AtorvastatinAtorvastatinRosuvastatin
Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values37191
SecondaryPercent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)

Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at 4 weeks after the start of the treatment period (after completion of administration of atorvastatin 10 mg alone) and at Week 16 or at discontinuation.

Time frame:
End of Week 4 to Week 16 or discontinuation
Reported as:
Mean · Percent change
Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)
Percent changeEzetimibe + AtorvastatinAtorvastatinRosuvastatin
Total Cholesterol-18.0 (-20.7 to -15.2)-10.3 (-13.1 to -7.4)1.9 (-1.7 to 5.5)
Triglycerides-0.8 (-14.4 to 12.8)0.2 (-10.9 to 11.4)14.7 (2.3 to 27.0)
High-Density Lipoprotein Cholesterol (HDL-C)4.5 (0.9 to 8.2)0.5 (-2.6 to 3.5)2.5 (-1.4 to 6.4)
Non-HDL-C-25.0 (-28.5 to -21.5)-13.7 (-17.0 to -10.3)2.0 (-2.6 to 6.5)
High Sensitivity C-Reactive Protein (Hs-CRP)49.0 (-43.2 to 141.3)9.9 (-24.1 to 43.9)25.7 (-4.8 to 56.1)
SecondaryPercent Change in Total Lipids and Hs-CRP

Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at the start of the treatment period (at start of administration of atorvastatin 10 mg alone) and at the end of study drug (Week 16 or discontinuation).

Time frame:
End of washout to Week 16 or discontinuation
Reported as:
Mean · Percent change
Percent Change in Total Lipids and Hs-CRP
Percent changeEzetimibe + AtorvastatinAtorvastatinRosuvastatin
Total Cholesterol-39.9 (-42.1 to -37.7)-32.8 (-35.8 to -29.7)-24.4 (-27.9 to -21.0)
Triglycerides-25.3 (-36.0 to -14.6)-18.8 (-29.8 to -7.8)-12.0 (-21.3 to -2.7)
High-Density Lipoprotein Cholesterol (HDL-C)10.3 (6.1 to 14.5)7.4 (3.7 to 11.0)9.9 (3.6 to 16.2)
Non-HDL-C-50.1 (-52.7 to -47.6)-41.4 (-44.8 to -37.9)-31.3 (-35.4 to -27.1)
High Sensitivity C-reactive Protein (Hs-CRP)73.0 (-84.4 to 230.4)-2.9 (-36.3 to 30.4)-13.6 (-39.7 to 12.6)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe + Atorvastatin—4/47 (8.5%)13/47 (27.7%)
Atorvastatin—1/46 (2.2%)5/46 (10.9%)
Rosuvastatin—0/32 (0%)9/32 (28.1%)
Most frequent serious events
Most frequent serious events
EventEzetimibe + AtorvastatinAtorvastatinRosuvastatin
PneumoniaInfections and infestations0/471/460/32
Chest discomfortGeneral disorders1/470/460/32
Heat illnessInjury, poisoning and procedural complications1/470/460/32
Carcinoid tumour of the gastrointestinal tractNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/470/460/32
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/470/460/32
Most frequent other events
Most frequent other events
EventEzetimibe + AtorvastatinAtorvastatinRosuvastatin
NasopharyngitisInfections and infestations7/475/463/32
HeadacheNervous system disorders1/470/463/32
HypertensionVascular disorders2/470/463/32
Blood creatine phosphokinase increasedInvestigations3/470/460/32
DizzinessNervous system disorders0/470/462/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ezetimibe + AtorvastatinAtorvastatinRosuvastatinTotal
Mean62.7 ± 11.459.3 ± 11.861.1 ± 12.061.0 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe + AtorvastatinAtorvastatinRosuvastatinTotal
Female25221764
Male22241561
Region of Enrollment
Region of Enrollment(participants)Ezetimibe + AtorvastatinAtorvastatinRosuvastatinTotal
Japan474632125
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Teramoto T, Sawada T, Iwamoto K, Daida H. Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia. Curr Ther Res Clin Exp. 2012 Feb;73(1-2):16-40. doi: 10.1016/j.curtheres.2012.02.002. PubMed 24653510 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2009 to primary completion in May 2010, 15 months.

Results were first posted in Aug 2011, 1 year 3 months after primary completion.

Of 40 phase 4 interventional studies under Hypercholesterolemia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2009
First posted
Mar 30, 2009
StartActual
Feb 1, 2009
Primary completionActual
May 1, 2010
CompletionActual
May 1, 2010
Results first posted
Aug 23, 2011
Last update
May 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00871351
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Mar 30, 2009
Start date
Feb 1, 2009
Primary completion
May 1, 2010
Completion
May 1, 2010
Results posted
Aug 23, 2011
Last update
May 23, 2024

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Atorvastatin

Start the discussion